Top

LATEST PUBLICATIONS



Uncovering How to Target Glioblastoma Cancer Cells

November 30, 2022

Via: GEN

Researchers from Flinders University and the South Australian Health and Medical Research Institute (SAHMRI) have been studying ways to uncover potential new drug therapies for the common and lethal brain cancer, glioblastoma. In a new study, the team discovered that […]


Why should pharma invest in digital products for those living with rare diseases?

November 23, 2022

Category: Industry, Pharma

Many will also face barriers to care, where access to specialists is limited and often geographically out of reach. That’s where technology coupled with user-centred design can help – bringing solutions and convenience to these pain points and positively impacting […]


Kids Born by C-Section May Have Weaker Response to Vaccines

November 16, 2022

Babies born via cesarean section may not mount as strong an immune response after some childhood vaccines compared to babies delivered vaginally, researchers suggest. Antibody levels can be checked in blood or saliva, and babies born vaginally had higher levels […]


Clinical Trials, Research and Development

Oxygen Consumption Detection in the Brain Advances with New Technique

December 1, 2022

Via: GEN

Scientists at the University of Pennsylvania say they have developed a novel optical method that uses a pair of macromolecular phosphorescent probes for the real-time monitoring of cerebral metabolic rate of oxygen consumption (CMRO2), concurrently with cerebral blood flow (CBF) […]


News

Genentech withdraws US indication of Tecentriq for bladder, urinary tract cancer

November 30, 2022

Via: Pharmaphorum

Following a consultation with the US Food and Drug Administration (FDA), and in accordance with the requirements of the FDA’s Accelerated Approval Program, Genentech has chosen to withdraw the US indication of atezolizumab for the treatment of adults with locally […]


Clinical Trials, Research and Development

X4 Pharmaceuticals announces positive top-line results for WHIM Syndrome drug

November 30, 2022

Via: Pharmaphorum

WHIM syndrome is a rare, inherited, combined immunodeficiency disease that inhibits the body’s ability to fight infections. In most patients, this is caused by over-signalling of the CXCR4/CXCL12 pathway, resulting in reduced mobilisation and trafficking of white blood cells from […]


Clinical Trials, Research and Development

Early Alzheimer’s Disease Detected by Urinary Biomarker

November 30, 2022

Via: GEN

The results of research headed by a team at Shanghai Jiao Tong University have identified formic acid as a sensitive urinary biomarker that can reveal early-stage Alzheimer’s disease (AD). The findings could potentially pave the way for inexpensive and convenient […]


Cell and Gene Therapy, Industry

AstraZeneca reveals its cell therapy ambitions with deal for startup

November 29, 2022

Via: Biopharma Dive

Once a fringe area of cancer research, cell therapy has exploded over the last decade. Since 2017, several treatments have come to market for blood cancers like leukemia and multiple myeloma, establishing cell therapy as a new class of medicines. […]


Clinical Trials, Research and Development

Lethal, Tick Borne, Hemorrhagic Fever Virus May Find Treatment in mAbs

November 29, 2022

Via: GEN

As far as emerging, zoonotic, viruses go—Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is one to watch. The disease, which is endemic in Africa, the Balkans, the Middle East, and some Asian countries, is considered a priority pathogen by the World Health […]


Industry, Vaccines

mRNA Vaccine Provides Broad Protection against All Known Influenza Subtypes

November 29, 2022

Via: GEN

Researchers at the Perelman School of Medicine at the University of Pennsylvania have developed an experimental multivalent mRNA-based vaccine against all 20 known subtypes of influenza virus. Their approach differs from previous attempts to craft a universal flu vaccine, by […]